The European Journal of Heart Failure is the international journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal publishes reviews and editorials in order to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome.
《欧洲心力衰竭杂志》是欧洲心脏病学会心力衰竭协会的国际期刊，致力于心力衰竭领域的知识进步。该杂志发表评论和社论，以提高对心力衰竭的理解，预防，调查和治疗。分子和细胞生物学、病理学、生理学、电生理学、药理学以及临床、社会和人口科学都构成心力衰竭学科的一部分。因此，请提交基础、临床和人口科学方面的文稿。也欢迎对护理、老年人护理、初级保健、卫生经济学和其他与心力衰竭相关的专业领域的原创贡献。
Treating oxidative stress in heart failure: past, present and future
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1320
Adrenomedullin in heart failure: pathophysiology and therapeutic application
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1366
The clinical significance of interleukin‐6 in heart failure: results from the BIOSTAT‐CHF study
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1482
Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1631
Effectiveness of the European Society of Cardiology/Heart Failure Association website ‘heartfailurematters.org’ and an e‐health adjusted care pathway in patients with stable heart failure: results of the ‘e‐Vita HF’ randomized controlled trial
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1354
Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1569
Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1437
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1347
Improving risk prediction in heart failure using machine learning
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1628
Aetiology‐based clinical scenarios predict outcomes of transcatheter edge‐to‐edge tricuspid valve repair of functional tricuspid regurgitation
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1547
Heart failure around the world
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1585
Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS‐HF trial
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1400
Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1375
Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non‐treatable Cardiac diseasE (SCIENCE)
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1412
Burden of medical co‐morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1404
Association between beta‐blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score‐matched analysis from the Swedish Heart Failure Registry
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1615
Clinical and research implications of serum versus plasma potassium measurements
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1371
Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50\u2009years
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1610
Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1630
Intravenous iron therapy in heart failure: a different perspective
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1434
Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1654
B‐type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1627
Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1341
Prescription patterns of anti‐diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1467
Prognostic value of baroreflex sensitivity in heart failure. A 2018 reappraisal
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1334
Physical activity tracking in correlation to conventional heart failure monitoring assessing improvements after transcatheter mitral and tricuspid valve repair
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1418
Heart failure after treatment for breast cancer
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1620
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1555
Dipeptidyl peptidase 3, a biomarker in cardiogenic shock and hopefully much more
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1649
Long‐term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1357
Heart failure with preserved ejection fraction in Asia: the far side of the moon?
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1335
De novo heart failure: where the journey begins
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1586
Electrophysiological interventions in the treatment of chronic heart failure: a comparison of the strength of evidence supporting cardiac resynchronization for electrical conduction delay and catheter ablation for atrial fibrillation
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1447
The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1416
Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN‐HF registry
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1640
Lessons from follow‐up after percutaneous mitral valve repair: ‘you are judged by the company you keep’
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1634
Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction\u2009—\u2009the importance of left ventricular remodelling
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1401
The Janus‐faced Fontan circulation: unravelling its elusive pathophysiology
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1415
Cardiac rehabilitation in heart failure after the ExTraMATCH II study: who still believes?
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1388
Angiotensin–neprilysin inhibition in de novo heart failure – starting off strong
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1675
It is time for consistency in the use of biomarkers in heart failure clinical trials
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1696
Common laboratory parameters as indicators of multi‐organ dysfunction in acute heart failure
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1466
Letter on ‘Pharmacy‐based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM‐CHF randomized controlled trial’
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1602
Heart Failure Atlas, a major project of the Heart Failure Association in concert with the European Society of Cardiology
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1445
March 2019 at a glance: epidemiology and clinical trials
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1258
Two‐year outcomes of the MITRA‐FR trial: towards an integrated approach in the evaluation of patients with secondary mitral regurgitation
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1652
The price of a failing heart
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1605
Transforming the interpretation of significance in heart failure trials
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1668
The never‐ending quest for the appropriate role of ultrafiltration
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1490
Myocardial dysfunction in breast cancer survivors: ‘you can observe a lot by just watching’
来源期刊：European Journal of Heart FailureDOI：10.1002/ejhf.1711
